15 Nov Navigating Startup Challenges: An Interview with Dr. Deborah Hemingway
Navigating startups from concept to market is a formidable challenge. Early-stage investors make a difference by guiding MedTech innovators to startup success.
The Key Tech team recently met with Dr. Deborah Hemingway, Managing Partner at investment firm Ecphora Capital. Dr. Hemingway shared her perspective on Maryland’s MedTech innovation ecosystem as well as the framework Ecphora Capital uses to guide MedTech startups to success.
Need to know
Maryland holds a unique position as a biotech hub. The state’s universities and research institutions are pipelines of innovation and talent. Prestigious business schools anchor the investor community. Maryland’s government also offers strong incentives for investors in local startups.
Ecphora Capital focuses on Maryland-based MedTech innovators, reflecting the lessons Dr. Hemingway learned as a researcher, entrepreneur, and investor:
Define your niche — Ecphora Capital’s strategy leverages the local MedTech and business ecosystems.
Build your networks — Ecphora Capital fosters strong networks among the research and investor communities that help unlock resources essential to young startups.
Mentorship matters — Dr. Hemingway enlists business leaders and scientists to mentor founders through membership in advisory circles or boards of directors.
The nitty-gritty
“My role as a venture capitalist,” Dr. Hemingway said, “is to ultimately make successful companies and to support and enable their success.” To that end, she developed the Ecphora Prelude, a framework to screen Ecphora Capital’s investments and guide companies to success:
1) Define the product-market fit
Any MedTech startup must answer a fundamental question: does the product address a genuine need that is top of mind for all stakeholders — patients, physicians, and payers?
2) Evaluate the product’s technical feasibility
Next are the practical aspects of translating ideas from the lab into real-world products. Beyond technology development, this parameter requires a comprehensive cost analysis to identify the financial implications of bringing a product to market.
3) Assess the IP landscape
Patent portfolios are the linchpins for any MedTech firm’s success. Understanding the state of the broader intellectual property landscape lets Ecphora Capital assess a startup’s market viability and potential weaknesses.
4) Quantify the market potential
Rather than initial public offerings, Dr. Hemingway explained, acquisitions are the most probable exits for MedTech startups, requiring deep analyses of past industry acquisitions to target the acquisition stage and price.
Data that made the difference
A recent Ecphora Capital investment is Novel Microdevices. Under the leadership of CEO Andrea Pais, the company develops clinical point-of-care diagnostic solutions that deliver PCR panels with 15-minute turnaround times. Dr. Hemingway described Novel Microdevices within the context of the Ecphora Prelude framework:
Product-market fit: Providing highly accurate PCR results within 15 minutes at the point of care lets physicians begin effective treatment immediately, benefiting patients and payers.
Technical feasibility: Novel Microdevices demonstrated key subsystems and is ready to develop a fully integrated functional prototype. This readiness level underscores the product’s feasibility.
IP landscape: The company possesses strong defenses to protect its product thanks to a multinational portfolio of patent applications, with divisional applications to cover additional claims.
Market potential: Novel Microdevices’ first panel diagnoses COVID and other respiratory infections. Future panels will diagnose hospital-acquired infections, women’s health, tropical diseases, or other infections. The company’s global market potential measures in the billions.
Ecphora Capital provides a compelling example of how a niche strategy yields potent market advantages. Check out the MedTech Speed to Data podcast here for more stories about the MedTech journey from concept to success.
A history nerd at heart, Alexis fits right into the quirky culture at Key Tech (though she still can’t speak binary). Weekends are spent chasing her two boys and spending time on her boat.
- Amplify MedTech – De-risking MedTech Product Development – From Idea to FDA - September 18, 2025
- Key Tech Joins GE HealthCare-led Team Advancing Bacterial Detection - August 7, 2025
- SPARK Webinar – The Importance of Early DFX - July 17, 2025